Vericel Co. Forecasted to Post FY2022 Earnings of ($0.43) Per Share (NASDAQ:VCEL)

Vericel Co. (NASDAQ:VCELGet Rating) – Research analysts at HC Wainwright reduced their FY2022 earnings estimates for shares of Vericel in a research note issued to investors on Thursday, November 10th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will earn ($0.43) per share for the year, down from their previous forecast of ($0.29). HC Wainwright has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Vericel’s current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for Vericel’s Q4 2022 earnings at $0.05 EPS, Q1 2023 earnings at ($0.19) EPS, Q2 2023 earnings at $0.03 EPS, Q3 2023 earnings at ($0.02) EPS, Q4 2023 earnings at $0.26 EPS and FY2023 earnings at $0.08 EPS.

VCEL has been the topic of several other reports. Stephens initiated coverage on shares of Vericel in a research note on Thursday, October 13th. They issued an “overweight” rating and a $40.00 price objective on the stock. BTIG Research cut shares of Vericel from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 9th. Truist Financial cut shares of Vericel from a “buy” rating to a “hold” rating in a research note on Wednesday, November 9th. Finally, StockNews.com began coverage on shares of Vericel in a research note on Wednesday, October 12th. They issued a “sell” rating on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $37.40.

Vericel Price Performance

VCEL stock opened at $23.80 on Monday. The company has a fifty day moving average price of $24.53 and a 200 day moving average price of $26.41. Vericel has a 12 month low of $17.30 and a 12 month high of $46.30. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -61.03 and a beta of 1.99.

Hedge Funds Weigh In On Vericel

Institutional investors and hedge funds have recently made changes to their positions in the stock. Newbridge Financial Services Group Inc. grew its stake in shares of Vericel by 100,000.0% during the 3rd quarter. Newbridge Financial Services Group Inc. now owns 2,002 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 2,000 shares during the period. Point72 Hong Kong Ltd acquired a new stake in Vericel in the 2nd quarter valued at about $73,000. Capital Advisory Group Advisory Services LLC acquired a new stake in Vericel in the 1st quarter valued at about $76,000. Captrust Financial Advisors grew its stake in Vericel by 43.4% in the 2nd quarter. Captrust Financial Advisors now owns 3,313 shares of the biotechnology company’s stock valued at $83,000 after acquiring an additional 1,002 shares during the last quarter. Finally, Lazard Asset Management LLC grew its stake in Vericel by 106.3% in the 2nd quarter. Lazard Asset Management LLC now owns 3,465 shares of the biotechnology company’s stock valued at $87,000 after acquiring an additional 1,785 shares during the last quarter.

Vericel Company Profile

(Get Rating)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.

Recommended Stories

Earnings History and Estimates for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.